Edition:
United States

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

4.01USD
26 May 2017
Change (% chg)

$-0.29 (-6.74%)
Prev Close
$4.30
Open
$4.27
Day's High
$4.27
Day's Low
$3.94
Volume
35,532
Avg. Vol
107,501
52-wk High
$10.30
52-wk Low
$1.85

Latest Key Developments (Source: Significant Developments)

Pernix Therapeutics qtrly loss per share $2.94
Monday, 15 May 2017 04:01pm EDT 

May 15 (Reuters) - Pernix Therapeutics Holdings Inc ::Pernix Therapeutics reports first quarter 2017 financial results and provides business update.Q1 revenue fell 8.6 percent to $29.7 million.Pernix Therapeutics Holdings Inc - qtrly loss per share $2.94.Pernix Therapeutics -net product revenues - other products increased by $0.1 million, or approximately 1%, during three months ended March 31, 2017.Pernix Therapeutics Holdings Inc says total principal amount of debt outstanding at March 31, 2017 was approximately $320.8 million.Pernix Therapeutics -agreed that a failure to repay all borrowings under revolving credit facility on or before July 31, would constitute an event of default.  Full Article

Pernix Therapeutics provides update on availability of Zohydro ER with BeadTek 20mg dose
Monday, 1 May 2017 08:00am EDT 

May 1 (Reuters) - Pernix Therapeutics Holdings Inc -:Pernix Therapeutics provides update on availability of zohydro® er with beadtek™ 20mg strength.Pernix Therapeutics - due to manufacturing issue with supplier, expects 20mg strength of zohydro er with beadtek to be on back order until at least q1 2018.Anticipates temporary stockout to impact overall zohydro er with beadtek prescription volume.Pernix Therapeutics - utilization of 10mg, 15mg and 30mg strengths of zohydro er with beadtek are expected to increase in order to fulfill patient needs.Continues to market and distribute other strengths of zohydro er with beadtek.  Full Article

Pernix Therapeutics announces Q4 and full year 2016 financial results
Tuesday, 28 Mar 2017 04:01pm EDT 

Pernix Therapeutics Holdings Inc - : Pernix Therapeutics announces fourth quarter and full year 2016 financial results . Q4 revenue fell 35 percent to $30.1 million .Net loss was $86.1 million for Q4 of 2016, compared to $81.7 million in q4 of 2015.  Full Article

Pernix Therapeutics receives favorable opinion in litigation with Actavis Laboratories
Thursday, 23 Feb 2017 08:00am EST 

Pernix Therapeutics Holdings Inc : Pernix Therapeutics Holdings - received favorable opinion in litigation with actavis laboratories regarding proposed generic version of zohydro er . Pernix Therapeutics-judge entered order enjoining actavis from engaging in commercial manufacture, use, offer to sell, or sale in u.s. For zohydro er .Pernix Therapeutics-judge also entered order enjoining actavis from importation into united states of actavis' anda product before expiration of 2 patents.  Full Article

Pernix Therapeutics provides update on arbitration
Friday, 3 Feb 2017 08:00am EST 

Pernix Therapeutics Holdings Inc : Pernix therapeutics provides update on arbitration . Pernix therapeutics - pernix and gsk had been in arbitration regarding claims related to treximet asset purchase agreement and supply agreement . Is reviewing opinions, including amount of interest, and intends to work with gsk to conclude matter . Tribunal also denied pernix's claim that gsk breached its obligations under supply agreement . Pernix therapeutics - on jan 31, , arbitration tribunal issued opinions in favor of gsk, awarding it damages, fees in amount of about $35 million, plus interes .Pernix therapeutics holdings - pernix has already paid to gsk, or into an escrow account, an aggregate of $16.5 million, which will offset total award.  Full Article

Pernix Therapeutics ceases discussions on possible restructuring of capital structure
Tuesday, 27 Dec 2016 09:45am EST 

Pernix Therapeutics Holdings Inc : On Dec 26, 2016, co ceased discussions with noteholders on possible consensual restructuring of co's capital structure . Co continues to analyze various strategic alternatives to proactively address its liquidity and capital structure - SEC filing .Estimates to have cash balance in low $30 million range,additional $12 million of liquidity available in credit facility at Dec 31.  Full Article

Pernix reports reverse stock split and corporate governance enhancements
Thursday, 13 Oct 2016 08:57am EDT 

Pernix Therapeutics Holdings Inc : Pernix Therapeutics announces reverse stock split and corporate governance enhancements . Pernix Therapeutics Holdings Inc - trading on post-split basis on nasdaq commencing at open of stock market on October 14, 2016 .Pernix Therapeutics Holdings Inc- board of directors unanimously approved a reverse split of its common stock at a ratio of 1-for-10.  Full Article

Pernix Therapeutics qtrly net loss per common share $0.47
Thursday, 11 Aug 2016 04:01pm EDT 

Pernix Therapeutics Holdings Inc : Pernix therapeutics reports second quarter 2016 financial results and business update . Pernix therapeutics holdings inc q2 revenue $36.7 mln vs i/b/e/s view $40.3 mln .Pernix therapeutics holdings inc qtrly net loss per common and potential common share $0.47.  Full Article

Pernix Therapeutics announces reorganization of Senior Management Team
Tuesday, 26 Jul 2016 05:41pm EDT 

Pernix Therapeutics Holdings Inc : Says graham miao appointed CFO and President . Pernix Therapeutics announces reorganization of senior management team . Pernix Therapeutics Holdings Inc says John Sedor will assume role of Chief Executive Officer on a permanent basis .Sanjay Patel, CFO, Terence Novak, COO, and Barry Siegel, Senior Vice President and General Counsel are no longer employed by Pernix..  Full Article

Pernix Therapeutics appointed John A. Sedor as CEO
Tuesday, 26 Jul 2016 05:19pm EDT 

Pernix Therapeutics Holdings Inc : On July 21 board appointed John A. Sedor as company's chief executive officer, effective July 26, 2016 - SEC filing . On July 21, 2016, the board appointed Graham Miao as the company's president and chief financial officer .Company will pay Miao a salary of $41,750 per month.  Full Article

More From Around the Web

BRIEF-Pernix Therapeutics provides update on availability of Zohydro ER with BeadTek 20mg dose

* Pernix Therapeutics provides update on availability of zohydro® er with beadtek™ 20mg strength